Hungary continues to strengthen its position in the pharmaceutical industry as Singapore-based Hongene Biotech has announced the establishment of its first European manufacturing facility in Gödöllő, just east of Budapest. The nearly EUR 94 million greenfield investment will create 150 new jobs and contribute significantly to Hungary’s export performance, according to the Hungarian Investment Promotion Agency.
Hongene Biotech Corporation, with close to 30 years of experience, is a key global player in the specialized field of nucleic acid production. The company is a world leader in the manufacturing of phosphoramidites and holds a leading position in producing raw materials for mRNA and oligonucleotide products. Since 2021, Hongene has played an important role in the global fight against COVID-19 by supplying large quantities of materials used in mRNA vaccines. Employing over 1,600 professionals worldwide, with a 400-member R&D team, the company has a strong presence in the United States, Japan, and China.
Gödöllő was selected as the site of Hongene’s first European manufacturing base. The greenfield investment will cover a 15-hectare area and include a facility of over 10,000 square meters, housing pharmaceutical ingredient production, quality assurance, environmental protection, warehousing, and utility infrastructure.
Production at the facility will focus on exports, making a meaningful contribution to Hungary’s export economy.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Hungary’s Growth Stalls as Inflation Returns to Target Range February 6, 2026
